Instructors :Dr. R P Singh, Dr. Manoj Khatri
Diabetes mellitus is a chronic disease that affects 415 million people worldwide. Despite treatment advances,
diabetic eye disease remains a leading cause of vision loss worldwide. Diabetic macular edema (DME) is a
common cause of vision loss in diabetic patients. The pathophysiology is complex and involves multiple
pathways that ultimately lead to central retinal thickening and, if untreated, visual loss. First-line treatment of
DME has evolved from focal/grid laser established by the Early Treatment of Diabetic Retinopathy Study
(ETDRS) to intravitreous pharmacologic therapy. Landmark prospective clinical trials examining the effect of
intravitreous injections of vascular endothelial growth factor (VEGF) inhibitors in the treatment of DME have
demonstrated improved visual outcomes over focal grid laser. This course focuses on the scientific evidence
treatment of DME, disease pathophysiology, clinical course, current treatment standards, and emerging novel
therapeutic approaches.
Case based discussions (commonly seen in routine practice) will include:
1. Newer concepts in understanding the Pathophysiology of DME
2. Clinical work up of a patient with DME
3. Newer diagnostic investigations in the management of DME
4. First line therapy in the management of DME
5. Combination therapy in the management of DME
6. Cataract surgery along with the management of DME
7. Emerging trends in the management of DME
8. Audience interaction
Leave a Comment